At the news
? BULLISHIMPACT 7/10 8-K filed Sep 4, 2026 at 06:01 ET
Ionis Pharmaceuticals announced FDA approval of ZANVASTRO (zilganersen) as the first and only disease-modifying treatment for Alexander disease (AxD), an ultra-rare progressive neurological disorder. The approval is based on a pivotal study that met its primary endpoint of gait speed stabilization (p=0.041), and Ionis also received a Priority Review Voucher. This marks Ionis's first independent launch from its neurology pipeline and adds a new revenue stream.
- FDA approved ZANVASTRO (zilganersen) for Alexander disease in pediatric and adult patients on September 3, 2026.
- ZANVASTRO is the first and only disease-modifying treatment for AxD, an ultra-rare disorder affecting ~1 in 1–3 million people.
- Pivotal study met primary endpoint: stabilization of gait speed at Week 61 (least square mean difference 33.3%, p=0.041).
- Ionis received a Rare Pediatric Disease Priority Review Voucher (PRV) with the approval.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access